Malignant Pleural Effusion Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Malignant Pleural Effusion Market Size Likely To Evolve From 2025 Through 2034?

The malignant pleural effusion market has experienced robust expansion in recent years. Projections indicate its size will increase from $4.42 billion in 2024 to $4.73 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 6.9%. Historically, this growth has been driven by factors such as the increasing use of indwelling pleural catheters, an enhanced emphasis on palliative care, a rise in clinical trials, improving reimbursement landscapes, and an uptick in metastatic malignancies.

The malignant pleural effusion market size is projected to undergo significant growth in the upcoming years. It is expected to expand to $6.12 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.7%. This anticipated growth throughout the forecast period can be attributed to factors such as expanding healthcare infrastructure, increasing government support, a rising number of cancer survivors, growing demand for home-based care, and advancements in liquid biopsy. Prominent trends for the forecast period include the integration of artificial intelligence in imaging tools, ongoing advancements in targeted cancer therapies, developments in pleurodesis, enhancements in biomarkers, and the expansion of clinical trials for novel therapeutic agents.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp

Which Major Market Drivers Are Shaping The Future Of The Malignant Pleural Effusion Market?

An increase in lung cancer diagnoses is projected to fuel the expansion of the malignant pleural effusion market moving ahead. Lung cancer is characterized by the unchecked proliferation of atypical cells within the lungs, often forming masses that disrupt typical respiratory function. The growing incidence of lung cancer is attributed to smoking and tobacco consumption, where extended exposure to dangerous substances in cigarettes harms lung tissue, initiates genetic mutations, and encourages the unrestricted multiplication of malignant cells, thereby substantially raising the risk of contracting the illness. Malignant pleural effusion signals advanced lung cancer by aiding the dissemination of tumors within the pleural space, resulting in compromised breathing and a less favorable outlook. As an illustration, data from January 2023, provided by the American Cancer Society Facts and Figures, a US-based professional organizations company, indicated that new lung and bronchus cancer cases were estimated at 236,740 for 2022 and 238,340 for 2023. Concurrently, estimated fatalities stood at 130,180 in 2022 and 127,070 in 2023. Consequently, the increasing prevalence of lung cancer is a key impetus for the expansion of the malignant pleural effusion market.

What Are The Major Segments Identified In The Malignant Pleural Effusion Market?

The malignant pleural effusionmarket covered in this report is segmented –

1) By Treatment: Systemic Therapy; Therapeutic Thoracentesis; Thoracic Drainage And Pleurodesis; Indwelling Pleural Catheter

2) By Diagnosis: Pleural Fluid Cytology; Immunohistochemical Tests; Imaging Tests; Pleural Thoracentosis; Pleuroscopy; Pleural Biopsy

3) By End Users: Hospitals; Ambulatory Clinics; Other End Users

Subsegments:

1) By Systemic Therapy: Chemotherapy; Targeted Therapy; Immunotherapy

2) By Therapeutic Thoracentesis: Single-Time Thoracentesis; Repeated Thoracentesis

3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis; Mechanical Pleurodesis; Biological Pleurodesis

4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter; Non-Tunneled Pleural Catheter

Which Competitive Trends Are Defining The Malignant Pleural Effusion Market Structure?

Leading companies active in the malignant pleural effusion market are directing their efforts toward developing innovative therapies, such as enzyme-targeting therapy, with the goal of improving treatment outcomes by specifically addressing enzymes involved in fluid accumulation. Enzyme-targeting therapy represents a medical strategy focused on designing drugs or treatments to precisely inhibit or modify the activity of enzymes associated with diseases. This type of therapy is commonly applied in conditions like cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to the progression of the illness. For instance, in September 2022, RS Oncology, LLC, a US-based biotechnology company, initiated the MITOPE clinical trial, which was a first-in-human Phase 1/2 trial conducted in the United Kingdom. This study is a Phase 1/2 trial assessing RSO-021, a novel PRX3 inhibitor specifically engineered to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.

Who Are The Key Multinational Companies Dominating The Malignant Pleural Effusion Market?

Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report

How Do Regional Market Performances Compare Within The Malignant Pleural Effusion Industry?

North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Malignant Pleural Effusion Market Report:

https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp

Browse Through More Reports Similar to the Global Malignant Pleural Effusion Market 2025, By The Business Research Company

Adult Malignant Glioma Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Malignant Melanoma Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795